2. Search Result
Search Result
Results for "

inactive control

" in MedChemExpress (MCE) Product Catalog:

74

Inhibitors & Agonists

4

Biochemical Assay Reagents

18

Peptides

1

Inhibitory Antibodies

3

Natural
Products

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-112306
    Ripretinib
    5+ Cited Publications

    DCC-2618

    		 c-Kit PDGFR FLT3 VEGFR Apoptosis Cancer
    Ripretinib (DCC-2618) is an orally bioavailable, selective KIT and PDGFRA switch-control inhibitor. Ripretinib (DCC-2618) targets and binds to both wild-type and mutant forms of KIT and PDGFRA specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. Ripretinib (DCC-2618) also inhibits multiple other kinase targets, such as FLT3 and KDR (or VEGFR-2) . DCC-2618 exerts antineoplastic effect and induces apoptosis .
    Ripretinib
  • HY-135416
    Streptolysin O
    2 Publications Verification

    		 Endogenous Metabolite Infection
    Streptolysin O, a group A streptococcal toxin, is a well-characterized oxygen-labile prototype of a cholesterol-binding bacterial exotoxin. Streptolysin O causes both lysis of cells and cardiotoxicity. Streptolysin O is widely used for the controlled permeabilization of cell membranes. Streptolysin O exists in two forms, a reduced active state and an oxidized reversibly inactive state .
    Streptolysin O
  • HY-15517
    KN-92
    Maximum Cited Publications
    9 Publications Verification

    		 CaMK Cancer
    KN-92 is an inactive derivative of KN-93, without CaM kinase inhibitory activity. KN-92 is intended to be used as a control compound in studies designed to elucidate the antagonist activities of KN-93. KN-93 is a cell-permeable, reversible and competitive CaMKII inhibitor .
    KN-92
  • HY-W007432
    RuPhos

    		Biochemical Assay Reagents Others
    RuPhos is a Buchwald ligand. In aqueous Suzuki-Miyaura catalytic transfer polymerization, RuPhos forms inactive Pd (RuPhos)2 with palladium and inhibits diffusion to improve polymerization controllability. RuPhos additional addition in anhydrous Kumada polymerization exacerbates catalyst deactivation and chain transfer, significantly impairing polymerization control .
    RuPhos
  • HY-108630
    U-73343
    5+ Cited Publications

    		 Phospholipase Others
    U-73343, works as a protonophore, is an inactive analog of U-73122 and can be used as a negative control. U-73343 dose-dependently inhibits acid secretion irrespective of the stimulant. U-73122 is a phospholipase C (PLC) and 5-LO (5-lipoxygenase) inhibitor with an IC50 of 1-2.1 μM for PLC .
    U-73343
  • HY-W011426
    Isopropyl palmitate

    Propan-2-yl hexadecanoate

    		 Environmental Pollutants Biochemical Assay Reagents Liposome Others
    Isopropyl palmitate is an fatty acid ester. Isopropyl palmitate can be used for design and characterization of bioactive bilayer films. The bilayer membrane not only has the ability to scavenge free radicals and inhibit lipid peroxidation, but also can inhibit the growth of known foodborne pathogens. Isopropyl palmitate can be used as an excipient, such as lubricant, oily carrier, solvent, controlled-release transdermal film. Pharmaceutical excipients, or pharmaceutical auxiliaries, refer to other chemical substances used in the pharmaceutical process other than pharmaceutical ingredients. Pharmaceutical excipients generally refer to inactive ingredients in pharmaceutical preparations, which can improve the stability, solubility and processability of pharmaceutical preparations. Pharmaceutical excipients also affect the absorption, distribution, metabolism, and elimination (ADME) processes of co-administered drugs .
    Isopropyl palmitate
  • HY-15517B
    KN-92 hydrochloride
    Maximum Cited Publications
    9 Publications Verification

    		 CaMK Cancer
    KN-92 hydrochloride is an inactive derivative of KN-93, without CaM kinase inhibitory activity. KN-92 hydrochloride is intended to be used as a control compound in studies designed to elucidate the antagonist activities of KN-93 .
    KN-92 hydrochloride
  • HY-121733
    PHGDH-inactive

    		Phosphoglycerate Dehydrogenase (PHGDH) Cancer
    PHGDH-inactive has no activity against PHGDH and serves as a negative control of NCT-502 and NCT-503 .
    PHGDH-inactive
  • HY-107477
    GSK8573

    		Epigenetic Reader Domain Cancer
    GSK8573 is an inactive control compound for GSK2801 (acetyl-lysine competitive inhibitor of BAZ2A and BAZ2B bromodomains). GSK8573 has binding activity to BRD9 with a Kd value of 1.04 μM and is inactive against BAZ2A/B and other bromodomain familiy. GSK8573 can be used as a structurally related negative control compound in biological experiments .
    GSK8573
  • HY-15517A
    KN-92 phosphate
    Maximum Cited Publications
    9 Publications Verification

    		 CaMK Autophagy Cancer
    KN-92 phosphate is an inactive derivative of KN-93, without CaM kinase inhibitory activity. KN-92 phosphate is intended to be used as a control compound in studies designed to elucidate the antagonist activities of KN-93. KN-93 is a cell-permeable, reversible and competitive CaMKII inhibitor .
    KN-92 phosphate
  • HY-164642
    Ribulose 1,5-bisphosphate

    RuBP

    		 Endogenous Metabolite Metabolic Disease
    Ribulose 1,5-bisphosphate (RUBP) is a vital photosynthetic intermediate and substrate. Ribulose 1,5-bisphosphate acts as both product and substrate for Thermococcus kodakarensis KOD1 R15Pi. Ribulose 1,5-bisphosphate tightly binds to inactive RuBP carboxylase sites in plant leaves.Ribulose 1,5-bisphosphate serves as the key substrate for CO2 fixation in photosynthesis. Ribulose 1,5-bisphosphate supports carboxylation and regeneration processes in photosynthesis. Ribulose 1,5-bisphosphate determines the dynamic transition temperature of photosynthetic control. Ribulose 1,5-bisphosphate can be used for photosynthesis and enzyme mechanism research .
    Ribulose 1,5-bisphosphate
  • HY-16994
    OICR-0547

    		WDR5 Cancer
    OICR-0547 is a negative control, closely related derivative of OICR-9429 (HY-16993). OICR-9429 is a novel small-molecule antagonist of the Wdr5-MLL interaction. OICR-0547 is an inactive control compound that no longer binds to WDR5 .
    OICR-0547
  • HY-153918A
    (S)-SKBG-1

    		Ligands for Target Protein for PROTAC Cancer
    (S)-SKBG-1 is an inactive and covalent NONO ligand, used for assay control..
    (S)-SKBG-1
  • HY-121954
    Necrostatin-1 (inactive control)

    Nec-1 (inactive control)

    		 Necroptosis Cancer
    Necrostatin-1 (Nec-1) (inactive control) is an inactive analog of Necrostatin-1 (HY-15760). Necrostatin-1 is a potent necroptosis inhibitor .
    Necrostatin-1 (inactive control)
  • HY-135416A
    Streptolysin O (≥1000000 units/mg)
    1 Publications Verification

    		 Endogenous Metabolite Infection
    Streptolysin O (≥1000000 units/mg) is a ≥1000000 units/mg Streptolysin O (HY-135416). Streptolysin O, a group A streptococcal toxin, is a well-characterized oxygen-labile prototype of a cholesterol-binding bacterial exotoxin. Streptolysin O causes both lysis of cells and cardiotoxicity. Streptolysin O is widely used for the controlled permeabilization of cell membranes. Streptolysin O exists in two forms, a reduced active state and an oxidized reversibly inactive state .
    Streptolysin O (≥1000000 units/mg)
  • HY-120343
    GSK106

    		Protein Arginine Deiminase Cardiovascular Disease Inflammation/Immunology Cancer
    GSK106 is an inactive control for the selective PAD4 inhibitors, GSK484 and GSK199 .
    GSK106
  • HY-13851
    PS47

    		PDK-1 Others
    PS47 is an inactive E-isomer of PS48. PS48 is an activator of PDK1. PS47 can be used as a negative control for PS48 .
    PS47
  • HY-145056
    ART615

    		DNA/RNA Synthesis Cancer
    ART615 is the related isomer of ART558. ART615, the inactive of ART558, elicits <10% Polθ inhibition at 12 µM, thus serving as a control for ART558 (IC50=7.9 nM) .
    ART615
  • HY-108437
    exo-IWR-1

    		Wnt Infection Cancer
    exo-IWR-1, an inactive stereoisomer of Endo-IWR-1, is a negative control of IWR-1 (HY-12238). IWR-1 is a tankyrase inhibitor which inhibits Wnt/β-catenin signaling pathway .
    exo-IWR-1
  • HY-161408A
    iGePhos1

    		PhosTACs Phosphatase Others
    iGePhos1 is an inactive GePhos1 (HY-161408) epimer used as a nonbinding negative control. iGephos1 lacks the phosphatase recruiting possibility .
    iGePhos1
  • HY-145081
    Pitnot-2

    		Drug Derivative Infection
    Pitnot-2 is an inactive analog of clathrin inhibitor Pitstop 2. Pitnot-2 can be used as negative control .
    Pitnot-2
  • HY-148745
    JG-258

    		HSP Cancer
    JG-258 is an inactive negative control for Hsp70 inhibitors .
    JG-258
  • HY-P3970D
    KQFK TFA

    		TGF-β Receptor Inflammation/Immunology
    KQFK TFA is the TFA salt form of KQFK (HY-P3970C). KQFK TFA is an inactive control of KRFK (HY-P3970). KRFK is a peptide derived from TSP-1 that can activate TGF-β .
    KQFK TFA
  • HY-115682
    (S)-ZINC-3573

    		Mas-related G-protein-coupled Receptor (MRGPR) Others
    (S)-ZINC-3573 is an inactive enantiomer of ZINC-3573. (R)-ZINC-3573 is a selective MRGPRX2 agonist. (S)-ZINC-3573 and (R)-ZINC3573 are effective and internally controlled probe-pairs for investigating the biology of primate-exclusive receptor .
    (S)-ZINC-3573
  • HY-W008003
    2-Hydroxybenzimidazole

    		Cytochrome P450 Others
    2-Hydroxybenzimidazole is an inactive compound targeting CYP1A1 and is mainly used as a control compound in the structure-activity relationship study of benzimidazole derivatives. 2-Hydroxybenzimidazole does not have the ability to induce CYP1A1 expression like its thiol or amino substituted derivatives .
    2-Hydroxybenzimidazole
  • HY-P1402
    [Glu27]-PKC (19-36)

    		PKC Others
    [Glu27]-PKC (19-36) is an inactive control for protein kinase C (PKC) (19-36). PKC (19-36) is a pseudosubstrate peptide inhibitor of protein kinase C, it may be responsible for maintaining the enzyme in the inactive form in the absence of allosteric activators such as phospholipids .
    [Glu27]-PKC (19-36)
  • HY-P1849A
    JAG-1, scrambled TFA
    1 Publications Verification

    scJag-1 TFA

    		 Notch Cardiovascular Disease
    JAG-1, scrambled (scJag-1) TFA is a scrambled sequence of JAG-1 (Jagged-1 protein). JAG-1, scrambled TFA has a random sequence of the amino acids that are the same as the active fragment. JAG-1, scrambled TFA is usually used as a negative control .
    JAG-1, scrambled TFA
  • HY-124479A
    γ-Lumicolchicine

    		Drug Derivative Cancer
    γ-Lumicolchicine is an inactive analogue of Colchicine (HY-16569) that can be used as an experimental control for Colchicine action .
    γ-Lumicolchicine
  • HY-P10168
    11R-CaN-CON

    		Phosphatase Others
    11R-CaN-CON is a control inactive peptide and can be used as a negative control for 11R-CaN-AID (HY-P10167) .
    11R-CaN-CON
  • HY-125143
    ABC34

    		MAGL Metabolic Disease
    ABC34 is an inactive control compound of JJH260. ABC34 does not inhibit the fluorophosphonate reactivity or fatty acid esters of hydroxy fatty acid (FAHFA) hydrolysis activity of AIG1. ABC34 can inhibit both ABHD6 and PPT122 .
    ABC34
  • HY-78931A
    (R,S,S,R,S)-Boc-Dap-NE

    		Drug Intermediate Cancer
    (R,S,S,R,S)-Boc-Dap-NE is the inactive isomer of Boc-Dap-NE (HY-78931), and can be used as an experimental control. Boc-Dap-NE, is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.
    (R,S,S,R,S)-Boc-Dap-NE
  • HY-118421
    Nullscript

    		Parasite HDAC Infection
    Nullscript is a negative control for Scriptaid. Nullscript is a known inactive analog of Scriptaid . Scriptaid is a representative HDAC inhibitor . Nullscript inhibits Cryptosporidium (C. parvum) growth with the IC50 value of 2.1 μM .
    Nullscript
  • HY-177662B
    Scrambled Sapablursen

    		Drug Derivative Metabolic Disease
    Scrambled Sapablursen is a sequence disorder of Sapablursen (HY-177662). Scrambled Sapablursen is inactive and can be used as a negative control for Sapablursen.
    Scrambled Sapablursen
  • HY-135843
    TH-263

    		LIM Kinase (LIMK) Cancer
    TH-263, a diaryl sulfonamide derivative, is inactive toward both LIMK1 and LIMK2 and thus can be used as negative control for TH-257 .
    TH-263
  • HY-P2243
    D-JBD19

    		JNK Neurological Disease
    D-JBD19 is an impermeable peptide that serves as an inactive control for the JNK inhibitor D-JNKI1 (HY-P0069). D-JNKI1 has neuroprotective effects .
    D-JBD19
  • HY-111457
    BAY-677
    1 Publications Verification

    		 Elastase Inflammation/Immunology
    BAY-677 is an inactive control for BAY-678. BAY-678 is an orally bioavailable, highly potent, selective and cell-permeable inhibitor of human neutrophil elastase (HNE), with an IC50 of 20 nM . BAY-678 is also nominated as a chemical probe to the public via the Structural Genomics Consortium (SGC) .
    BAY-677
  • HY-118914
    Glucagon receptor antagonist inactive control

    		GCGR
    Glucagon receptor antagonist inactive control (Compound 2) is a compound structurally similar to the glucagon receptor (GCGR) antagonist Glucagon receptor antagonist (Compound 1) but lacks antagonistic activity against glucagon receptor (GCGR). Glucagon receptor antagonist inactive control can be used as a negative control to study mechanisms related to glucagon receptor-mediated signaling pathways .
    Glucagon receptor antagonist inactive control
  • HY-170859A
    AH081

    		PROTACs Casein Kinase Cancer
    AH081 (Compound 38) is a CK1δ/ε PROTAC degrader. AH081 is the negative control compound of AH078 (HY-170859). AH081 has inhibitory but no degradation activity for CK1δ/ε by using an inactive stereoisomer of the VHL ligand . Pink: CK1δ/ε ligand (HY-148251); Blue: VHL ligase ligand (HY-125845B); Black: linker
    AH081
  • HY-112306R
    Ripretinib (Standard)

    DCC-2618 (Standard)

    		 c-Kit PDGFR FLT3 VEGFR Apoptosis Reference Standards Cancer
    Ripretinib (Standard) is the analytical standard of Ripretinib. This product is intended for research and analytical applications. Ripretinib (DCC-2618) is an orally bioavailable, selective KIT and PDGFRA switch-control inhibitor. Ripretinib (DCC-2618) targets and binds to both wild-type and mutant forms of KIT and PDGFRA specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. Ripretinib (DCC-2618) also inhibits multiple other kinase targets, such as FLT3 and KDR (or VEGFR-2) . DCC-2618 exerts antineoplastic effect and induces apoptosis .
    Ripretinib (Standard)
  • HY-113894
    Retreversine

    		Aurora Kinase Cancer
    Retreversine is an inactive control for Reversine. Reversine is a novel class of ATP-competitive Aurora kinase inhibitor .
    Retreversine
  • HY-136453A
    CR-1-30-B

    		Mucin Drug Isomer Cancer
    CR-1-30-B is an inactive enantiomer of CR-1-31-B. CR-1-30-B, as a control, is inactive against eIF4A and has no apparent effect on the induction of MUC1-C translation .
    CR-1-30-B
  • HY-129253
    GSK984

    		HPV Infection
    GSK984 is an inactive control probe for GSK983 (HY-119098), a dihydroorotate dehydrogenase (DHODH) inhibitor with antiviral activity .
    GSK984
  • HY-P2670
    SN50M

    		NF-κB Others
    SN50M, a mutant peptide of SN50 (HY-P0151), is a cell membrane-permeable inactive control peptide .
    SN50M
  • HY-P3970C
    KQFK

    		TGF-β Receptor Others
    KQFK is an inactive control of KRFK (HY-P3970). KRFK is a peptide derived from TSP-1 that can activate TGF-β .
    KQFK
  • HY-101125B
    D-Moses

    D-45

    		 Epigenetic Reader Domain Cancer
    D-Moses (D-45) is an enantiomer of L-Moses (HY-101125). L-Moses (L-45) is a potent and selective p300/CBP-associated factor (PCAF) bromodomain (Brd) inhibitor. D-Moses shows no observable binding for PCAF Brd. D-Moses can be used as an inactive control compound to L-Moses .
    D-Moses
  • HY-119857
    AGK7

    SIRT2 Inhibitor,inactive control

    		 Sirtuin Neurological Disease
    AGK7 is a potent inhibitor of sirtuin 2 (SIRT2). AGK7 rescues alpha-synuclein toxicity and modified inclusion morphology in a cellular model of Parkinson's disease. AGK7 protects against dopaminergic cell death both in vitro and in a Drosophila model of Parkinson's disease .
    AGK7
  • HY-126300A
    SGC6870N

    		Histone Methyltransferase Cancer
    SGC6870N is inactive against PRMT6 and can be utilized as a negative control. SGC6870N is an inactive enantiomer of SGC6870 (HY-126300) .
    SGC6870N
  • HY-P1312
    LRGILS-NH2

    		Protease Activated Receptor (PAR) Others
    LRGILS-NH2 is a reverse-sequence protease-activated receptor-2 (PAR-2)-inactive, negative control, and SLIGRL-NH2 is a PAR-2-activating peptide .
    LRGILS-NH2
  • HY-P1312A
    LRGILS-NH2 TFA

    		Protease Activated Receptor (PAR) Others
    LRGILS-NH2 TFA is a reverse-sequence protease-activated receptor-2 (PAR-2)-inactive, negative control, and SLIGRL-NH2 is a PAR-2-activating peptide .
    LRGILS-NH2 TFA
  • HY-106029
    4α-TPA

    α-TPA

    		 PKC SphK NF-κB Cancer
    4α-TPA is an inactive form of TPA, and is used as a negative control for TPA-activated events .
    4α-TPA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: